Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


eISSN: 1643-3750

Published: 2019-08-19

The Specific Choice of Transrectal Ultrasound-Guided Prostate Biopsy Scheme Based on Prostate Specific Antigen and Prostate Specific Antigen Density

Yue Chen, Xingkang Jiang, Ranlu Liu, Zhihong Zhang, Fei Luo, Shiyong Qi, Yong Xu

(Department of Urology, Second Hospital of TianJin Medical University, TianJin Institute of Urology, Tianjin, China (mainland))

Med Sci Monit 2019; 25:6230-6235

DOI: 10.12659/MSM.915826

BACKGROUND: Although magnetic resonance imaging (MRI)-targeted biopsy and saturation biopsy can improve the accuracy of prostate biopsy, transrectal ultrasound (TRUS)-guided prostate biopsy is still the cornerstone for diagnosis of prostate cancer. However, it is not clear whether it is necessary to perform the same TRUS-guided biopsy scheme for patients with different prostate specific antigen (PSA) or prostate specific antigen density (PSAD) levels. The purpose of this study was to evaluate the optimal core number for specific suspected prostate cancer patients.
MATERIAL AND METHODS: There were 398 patients who underwent 12-core biopsy scheme, who were included in this retrospective analysis. The 12-core scheme incorporated a classic sextant scheme and 4-core biopsies from the base and middle regions bilaterally. The cancer detection rates of patients with different PSA or PSAD levels between the 12-core, sextant, 4-core, and 2-core biopsy were compared.
RESULTS: The differences in cancer detection rates between the 12-core biopsy scheme and the sextant biopsy scheme were significant in patients with PSA <20 ng/mL or PSAD <0.3. There were no differences in the cancer detection rates between the 12-core biopsy scheme and the 4-core biopsy scheme in patients with PSA ≤50 ng/mL or PSAD ≤1.0. There were significant differences between 12-core and 2-core scheme when PSA ≤70 ng/mL or PSAD ≤1.5.
CONCLUSIONS: We recommend that the 12-core biopsy should be used for patients with PSA <20 ng/mL or PSAD <0.3. The biopsy scheme in patients with PSA 20-50 ng/mL or PSAD 0.3-1.0 should be considered in combination with DRE and MRI. For patients with PSA >50 ng/mL or PSAD >1.0, we recommend 6-core or 4-core biopsy by comprehensively considering multiple factors. The 2-core biopsy is recommended for patients with PSA >70 ng/mL or PSAD >1.5.

Keywords: Biopsy, Prostate-Specific Antigen, Ultrasound, High-Intensity Focused, Transrectal

Related Articles (0)

Coming Soon...

Published: 2019-08-19

Decreased Expression of Long Non-Coding RNA GMDS Divergent Transcript (GMDS-DT) is a Potential Biomarker ...

Duo Wang, Xiufang Du, Tao Bai, Miao Chen, Jie Chen, Junjie Liu, Lequn Li, Hang Li, Chunyan Zhang

Med Sci Monit 2019; 25:6221-6229

DOI: 10.12659/MSM.917663

Published: 2019-08-18

A 5-Gene Prognostic Combination for Predicting Survival of Patients with Gastric Cancer

Liang Song, Xiao-Yan Wang, Xiao-Feng He

Med Sci Monit 2019; 25:6213-6220

DOI: 10.12659/MSM.914815